AtriCure price target raised to $53 from $51 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on AtriCure (ATRC) to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.